人肝癌亚力山大细胞PLCPRF5

细胞名称

人肝癌亚力山大细胞PLCPRF5                  

货物编码

BFN60800680

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研用途 2类

培养体系

DMEM高糖培养基（Hyclone）+10%胎牛血清（Gibco）+1%双抗（Hyclone）

培养温度

37℃

二氧化碳浓度

5%

简介

人肝癌亚力山大细胞PLCPRF5细胞分泌HBsAg。人肝癌亚力山大细胞PLCPRF5细胞由青旗（上海）生物技术发展有限公司于2017年引种自ATCC(CRL-8024)。

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: JFCR45 cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Characteristics: Contains at least 7 copies of integrated HBV genomes.

Characteristics: Secretes hepatitis virus B surface antigen (HBsAg).

Characteristics: Has lost chromosome Y.

Doubling time: 35-40 hours (PubMed=63998).

Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Caution: Often called PLC8024 in Chinese literature probably because of a concatenation between PLC/PRF/5 and ATCC-8024.

Misspelling: PCL/PRF/5; In Cosmic 873402.

STR信息

Amelogenin: X

CSF1PO: 10

D13S317: 11,12

D16S539: 13

D5S818: 12

D7S820: 9,11

TH01: 8

TPOX: 8

vWA: 15,16

参考文献

PubMed=63998

Alexander J.J., Bey E.M., Geddes E.W., Lecatsas G.

Establishment of a continuously growing cell line from primary carcinoma of the liver.

S. Afr. Med. J. 50:2124-2128(1976)

PubMed=184551

Alexander J.J., Bey E.M., Whitcutt J.M., Gear J.H.S.

Adaptation of cells derived from human malignant tumours to growth in vitro.

S. Afr. J. Med. Sci. 41:89-98(1976)

PubMed=187208; DOI=10.1038/bjc.1976.205

MacNab G.M., Alexander J.J., Lecatsas G., Bey E.M., Urbanowicz J.M.

Hepatitis B surface antigen produced by a human hepatoma cell line.

Br. J. Cancer 34:509-515(1976)

PubMed=6160110

Daemer R.J., Feinstone S.M., Alexander J.J., Tully J.G., London W.T., Wong D.C., Purcell R.H.

PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity.

Infect. Immun. 30:607-611(1980)

PubMed=6248960; DOI=10.1126/science.6248960

Knowles B.B., Howe C.C., Aden D.P.

Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Science 209:497-499(1980)

PubMed=6268737; DOI=10.1099/0022-1317-53-1-105

Oefinger P.E., Bronson D.L., Dreesman G.R.

Induction of hepatitis B surface antigen in human hepatoma-derived cell lines.

J. Gen. Virol. 53:105-113(1981)

PubMed=6275024; DOI=10.1099/0022-1317-57-1-95

Koshy R., Maupas P., Muller R., Hofschneider P.H.

Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.

J. Gen. Virol. 57:95-102(1981)

PubMed=6889516; DOI=10.1016/0277-5379(82)90010-4

Sattler F.R., Paolucci S., Kreider J.W., Ladda R.L.

A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice.

Eur. J. Cancer Clin. Oncol. 18:381-389(1982)

PubMed=6555060; DOI=10.1007/BF00199162

Keong A., Herman J., Rabson A.R.

Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity.

Cancer Immunol. Immunother. 15:183-187(1983)

PubMed=6225510; DOI=10.1007/BF00199161

Keong A., Rabson A.R.

Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells.

Cancer Immunol. Immunother. 15:178-182(1983)

PubMed=2414854

Aspinall S., Alexander J.J.

Hepatitis B virus gene expression in two cell lines, one derived from a natural human infection, the other experimentally infected in vitro.

S. Afr. Med. J. 68:751-754(1985)

PubMed=2992761; DOI=10.1016/0165-4608(85)90033-0

Pinto M.R., Bey E., Bernstein R.

The PLC/PRF/5 human hepatoma cell line. I. Reevaluation of the karyotype.

Cancer Genet. Cytogenet. 18:11-18(1985)

PubMed=2992762; DOI=10.1016/0165-4608(85)90034-2

Bowcock A.M., Pinto M.R., Bey E., Kuyl J.M., Dusheiko G.M., Bernstein R.

The PLC/PRF/5 human hepatoma cell line. II. Chromosomal assignment of hepatitis B virus integration sites.

Cancer Genet. Cytogenet. 18:19-26(1985)

PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315

Aspinall S., Alexander J., Bos P.

Comparative expression of hepatitis B virus antigens in several cell model systems.

J. Gen. Virol. 67:2315-2323(1986)

DOI=10.1007/978-4-431-68349-0_4

Alexander J.J.

Human hepatoma cell lines.

(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x

Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.

Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.

Eur. J. Biochem. 165:699-704(1987)

PubMed=2542205; DOI=10.1111/j.1349-7006.1989.tb02290.x

Tsuda H., Hirohashi S., Shimosato Y., Ino Y., Yoshida T., Terada M.

Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma.

Jpn. J. Cancer Res. 80:196-199(1989)

PubMed=1661347; DOI=10.2302/kjm.40.139

Saito H., Morizane T., Watanabe T., Kagawa T., Miyaguchi S., Kumagai N., Tsuchimoto K., Tsuchiya M.

Proto-oncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5.

Keio J. Med. 40:139-145(1991)

PubMed=8389256; DOI=10.1093/carcin/14.5.987

Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Carcinogenesis 14:987-992(1993)

PubMed=7874267; DOI=10.1007/BF02349278

Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K., Yachi A.

Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.

J. Gastroenterol. 29:727-732(1994)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x

Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.

HLA expression in hepatocellular carcinoma cell lines.

Clin. Exp. Immunol. 97:328-333(1994)

DOI=10.11418/jtca1981.16.3_173

Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ohashi R., Namba M.

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108

Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

Cell. Immunol. 177:176-181(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=9359923; DOI=10.18926/AMO/30789

Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ishioka C., Namba M.

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Acta Med. Okayama 51:261-265(1997)

PubMed=10523694; DOI=10.3892/or.6.6.1267

Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.

Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.

Oncol. Rep. 6:1267-1271(1999)

PubMed=11050057; DOI=10.1053ep.2000.19349

Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-L., Johnson P.J.

A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.

Hepatology 32:1060-1068(2000)

PubMed=12029633; DOI=10.1053ep.2002.33683

Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Hepatology 35:1476-1484(2002)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

PubMed=20069059; DOI=10.1155/2010/437143

Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.

Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.

J. Biomed. Biotechnol. 2010:437143-437143(2010)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402

Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218-2218(2013)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311

Cevik D., Yildiz G., Ozturk M.

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

World J. Gastroenterol. 21:311-317(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29892436; DOI=10.1098/rsos.172472

Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.

Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.

R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)